To Panel or Not To Panel? FDA May Address Criteria In Upcoming Guidance
This article was originally published in The Gray Sheet
Executive Summary
Industry advocates anticipate FDA will be issuing guidance on the criteria it uses to determine if a premarket submission warrants advisory panel review. The time burden of panel meetings was demonstrated by FY 2013-received PMAs, which were subject to a greater than normal proportion of panel meetings and a spike in decision times.